EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Comparison of pharmacokinetics of sitagliptin 100 mg tablets in healthy Asian Indian and Thai volunteers

Anurag Saro, Arshad H Khuroo, Sudershan Kumar, Sovan Maiti

Indian Journal of Pharmacology · 2026

DOI: 10.4103/ijp.ijp_44_26 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Indian Journal of Pharmacology, 2026. Verfasst von Anurag Saro und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Pharmacokinetics Sun Pharmaceutical Industries Limited, Gurugram, Haryana, India. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents, Sitagliptin Phosphate. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The purpose of this study was to compare the Pharmacokinetics of Sitagliptin 100 mg tablets in healthy Asian Indian and Thai Volunteers. MATERIALS AND METHODS: Two independent crossover evaluations were conducted in healthy adults of Indian (Study 1) and Thai (Study 2) origin. Participants received a single 100 mg dose of either test or reference sitagliptin tablet under fasting conditions, followed by the alternate product after a washout. Plasma sitagliptin was quantified by validated LC-MS/MS, and non-compartmental analysis yielded Cmax, AUC 0–t , AUC 0–∞ , and T max. Bioequivalence was concluded when 90% confidence intervals (CIs) for geometric mean ratios fell within 80%–125%. RESULTS: For both Indian and Thai cohorts, point estimates and 90% CIs for Cmax, AUC 0–t and AUC 0–∞ were contained in predefined 80%–125% interval, and no clinically meaningful differences between formulations were detected. Exposure metrics were comparable across the two ethnic groups. CONCLUSIONS: In the two studies conducted in healthy Asian Indian and Thai volunteers, the test and reference formulation of sitagliptin 100 mg exhibited comparable pharmacokinetics profiles and were bioequivalent according to the regulatory definition based on rate and extent of absorption. Both formulations were well tolerated by all volunteers. Similar C max and AUC values were observed across both populations, indicating that ethnicity has no significant effect on the pharmacokinetics of sitagliptin. Therefore, bioequivalence results obtained in one population can be extrapolated to others.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsSitagliptin PhosphateAdultFemaleHumansMaleYoung AdultArea Under CurveCross-Over StudiesHealthy VolunteersIndiaTabletsTandem Mass SpectrometryThailandTherapeutic EquivalencySouth Asian People

Stichwörter der Autor:innen

Bioequivalencehealthy volunteerspharmacokineticsitagliptin

Substanzen

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsSitagliptin PhosphateTablets

Autor:innen und Institutionen

  • Clinical Pharmacology and Pharmacokinetics Sun Pharmaceutical Industries Limited, Gurugram, Haryana, India.

Zitieren

APA

Saro, A., Khuroo, A. H., Kumar, S., & Maiti, S. (2026). Comparison of pharmacokinetics of sitagliptin 100 mg tablets in healthy Asian Indian and Thai volunteers. Indian Journal of Pharmacology. https://doi.org/10.4103/ijp.ijp_44_26

Vancouver

Saro A, Khuroo AH, Kumar S, Maiti S. Comparison of pharmacokinetics of sitagliptin 100 mg tablets in healthy Asian Indian and Thai volunteers. Indian Journal of Pharmacology. 2026. doi:10.4103/ijp.ijp_44_26

BibTeX
@article{Saro2026,
  author = {Saro, Anurag and Khuroo, Arshad H and Kumar, Sudershan and Maiti, Sovan},
  title = {Comparison of pharmacokinetics of sitagliptin 100 mg tablets in healthy Asian Indian and Thai volunteers},
  journal = {Indian Journal of Pharmacology},
  year = {2026},
  doi = {10.4103/ijp.ijp_44_26}
}
Kostenlos starten →